ir.actiniumpharma.com Open in urlscan Pro
3.72.124.16  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About
   * Overview
   * Management Team
   * Board of Directors
   * Partners
 * Product Pipeline
   * Overview
   * Iomab-B
   * Iomab-ACT for Gene & Cell Therapy Conditioning
   * Clinical Trial Information
   * Publications
 * AWE Technology
 * Investors
    * Investor Relations
    * Overview
   
    * News / Events
    * Press Releases
    * In The News
    * IR Calendar
    * Video Gallery
    * Proxy Information
    * Shareholder Letters
    * Email Alerts
   
    * Company Info
    * Profile
    * Presentations & Webinars
    * Contacts
    * Analyst Coverage
    * FAQ
   
    * Stock Data
    * Quote
    * Charts
    * Historical Data
   
    * SEC Filings
    * All SEC Filings
    * Annual Reports
    * Quarterly Reports
   
    * Governance
    * Board of Directors
    * Board Committees
    * Governance Documents

 * Careers
 * Contact


 * Home
 * Investors
 * Investor Relations


Investors
 * Overview
 * News / Events
 * Company Information
 * Stock Data
 * SEC Filings
 * Corporate Governance

 * Email Alerts
 * Contacts
 * Twitter
 * RSS News Feed


INVESTOR RELATIONS


LATEST NEWS


ACTINIUM TO PRESENT AT THE CANTOR FITZGERALD ONCOLOGY, HEMATOLOGY & HEMEONC
CONFERENCE

Sep 26, 2022
Read Press Release


LATEST FINANCIAL RESULTS


Q2 2022

Quarterly Results

Ended Jun 30, 2022
PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL


STOCK INFORMATION


NYSE AMERICAN

ATNM


PRICE

$7.21


CHANGE

0.17


VOLUME

50.31k


MARKET CAP

$181.71m


52 WEEK LOW/HIGH

4.41 - 9.21


DAY LOW/HIGH

7.08 - 7.50


COMPANY OVERVIEW

Download

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing targeted radiotherapies to deliver cancer-killing radiation with
cellular level precision to treat patients with high unmet needs not addressed
by traditional cancer therapies. Actinium's current clinical pipeline is led by
ARCs or Antibody Radiation-Conjugates that are being applied to targeted
conditioning, which is intended to selectively deplete a patient's disease or
cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant,
Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment
of these transplanted cells with minimal toxicities. Actinium's targeted
conditioning ARCs seek to improve patient outcomes and access to these
potentially curative treatments by eliminating or reducing the non-targeted
chemotherapy that is used for conditioning in standard practice currently. Our
lead product candidate, I-131 apamistamab (Iomab-B) has been studied in several
hundred patients including in the recently completed, 150-patient, pivotal Phase
3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia
(SIERRA) trial for BMT conditioning. Iomab-ACT, low dose I-131 apamistamab is
being studied as a targeted conditioning agent in a Phase 1 study with a CD19
CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center. In addition, we
are leaders in the field of Actinium-225 alpha therapies. Actimab-A, our
clinical stage CD33 targeting ARC alpha therapy has been studied in nearly 150
patients including our ongoing combination trials with the salvage chemotherapy
CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical
programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.
This is where our intellectual property portfolio of over 170 patents, know-how,
collective research and expertise in the field are being leveraged to construct
and study novel ARCs and ARC combinations such as with CD47 immunotherapies to
bolster our pipeline for strategic purposes. Our AWE technology platform is
currently being utilized in a collaborative research partnership with Astellas
Pharma, Inc. for solid tumor theranostics and with AVEO Oncology to create an
Actinium-225 HER3 targeting radiotherapy.


CONTACT INFORMATION

Investor Relations
Actinium Pharmaceuticals, Inc.
275 Madison Avenue
Suite 702
New York, NY 10016
Investorrelations@actiniumpharma.com


Transfer Agent
Action Stock Transfer
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: (801) 274-1088
F: (801) 274-1099



EMAIL SIGN UP

Receive the latest news, events and updates!

Sign Up Now
© 2022 Actinium Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us